SpinalCyte’s IRB Approval for Phase I Clinical Trial

SpinalCyte received Institutional Review Board approval to commence randomized, placebo-controlled, double-blind Phase I clinical trials with CybroCell dermal fibroblast cell product in the treatment of degenerative disc disease.

Trials will enroll 18 patients receiving CybroCell alone, in combination with platelet-rich plasma or saline only....

document icon

You are out of free articles for this month

Subscribe as a Guest for $0 and unlock a total of 5 articles per month.

You are out of five articles for this month

Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.


Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.

Contact Us